MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing innovative invariant natural killer T (iNKT) cell therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly results and provide a corporate update. Investors can access the call through dial-in numbers for New York (646-307-1963) and USA/Canada (800-715-9871) using Conference ID 1149380, or via webcast on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, INKT declined 8.34%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $63M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 1149380
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at:
https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/qjwyn82w
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
communications@minktherapeutics.com
Source: MiNK Therapeutics
FAQ
When will MiNK Therapeutics (INKT) report Q2 2025 earnings?
How can investors access MiNK Therapeutics' Q2 2025 earnings call?
What type of cell therapies is MiNK Therapeutics developing?
What time is MiNK Therapeutics' Q2 2025 earnings call?
